DexCom (DXCM) Given “Sell” Rating at Northland Securities

Northland Securities restated their sell rating on shares of DexCom (NASDAQ:DXCM) in a research note released on Tuesday morning. They currently have a $40.00 target price on the medical device company’s stock.

A number of other analysts have also commented on DXCM. JPMorgan Chase & Co. lowered shares of DexCom from an overweight rating to a neutral rating and reduced their price target for the stock from $93.00 to $71.00 in a research note on Thursday, September 28th. Citigroup lowered shares of DexCom from an outperform rating to a market perform rating in a research note on Thursday, September 28th. Jefferies Group reiterated a buy rating and issued a $91.00 price target on shares of DexCom in a research note on Thursday, September 28th. Wedbush reiterated an outperform rating and issued a $76.00 price target (down from $85.00) on shares of DexCom in a research note on Thursday, September 28th. Finally, Raymond James Financial reiterated a market perform rating and issued a $49.50 price target (down from $76.00) on shares of DexCom in a research note on Thursday, September 28th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $68.50.

Shares of DexCom (NASDAQ:DXCM) traded down $0.23 during mid-day trading on Tuesday, hitting $56.05. 1,157,253 shares of the stock were exchanged, compared to its average volume of 1,372,633. DexCom has a 52-week low of $42.62 and a 52-week high of $86.32. The company has a market capitalization of $4,890.91, a price-to-earnings ratio of -98.33 and a beta of 0.31. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.11. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%. sell-side analysts forecast that DexCom will post -0.65 EPS for the current year.

In other news, Director Steven R. Altman purchased 10,000 shares of the company’s stock in a transaction on Monday, November 6th. The stock was acquired at an average cost of $49.61 per share, for a total transaction of $496,100.00. Following the completion of the transaction, the director now directly owns 4,353 shares in the company, valued at approximately $215,952.33. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the completion of the transaction, the executive vice president now owns 65,049 shares of the company’s stock, valued at $2,915,496.18. The disclosure for this sale can be found here. Insiders have sold 48,140 shares of company stock valued at $2,727,176 over the last 90 days. 1.70% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Winslow Capital Management LLC bought a new position in shares of DexCom in the second quarter worth approximately $117,451,000. State Street Corp boosted its position in shares of DexCom by 2.5% in the second quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after purchasing an additional 37,581 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of DexCom by 3.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 265,019 shares of the medical device company’s stock worth $12,967,000 after purchasing an additional 8,171 shares during the period. Peregrine Capital Management LLC boosted its position in shares of DexCom by 24.5% in the third quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock worth $19,348,000 after purchasing an additional 77,868 shares during the period. Finally, Macquarie Group Ltd. boosted its position in shares of DexCom by 67.2% in the second quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock worth $17,746,000 after purchasing an additional 97,479 shares during the period.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/dexcom-dxcm-given-sell-rating-at-northland-securities/1848570.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish


Leave a Reply

 
© 2006-2018 BBNS.